LIVTENCITY is indicated for the treatment of cytomegalovirus (CMV) infection and/or disease that
are refractory (with or without resistance) to one or more prior therapies, including ganciclovir,
valganciclovir, cidofovir or foscarnet in adult and pediatric patients (12 years of age and older
and weighing at least 35 kg) who have undergone a haematopoietic stem cell transplant (HSCT) or
solid organ transplant (SOT). (see sections 4.2 and 5.1).
Consideration should be given to official guidance on the appropriate use of antiviral agents.

LIVTENCITY should be initiated by a physician experienced in the management of patients who have
undergone solid organ transplant or haematopoietic stem cell transplant.
Posology
The recommended dosage of Livtencity in adults and pediatric patients (12 years of age and older and
weighing at least 35 kg) is 400 mg (two 200 mg tablets) taken orally twice daily with or without food
(see section 5.1 and 5.2). Treatment duration may need to be individualised based on the clinical
characteristics of each patient

Co-administration with CYP3A inducers
Co-administration of LIVTENCITY with the strong cytochrome P450 3A (CYP3A) inducers
rifampicin, rifabutin or St. John’s wort is not recommended due to potential for a decrease in efficacy
of maribavir.
If co-administration of LIVTENCITY with other strong or moderate CYP3A inducers (e,g.,
carbamazepine, efavirenz, phenobarbital and phenytoin) cannot be avoided, the LIVTENCITY dose
should be increased to 1 200 mg twice daily (see sections 4.4, 4.5 and 5.2).
Missed dose
Patients should be instructed that if they miss a dose of LIVTENCITY, and the next dose is due within
the next 3 hours, they should skip the missed dose and continue with the regular schedule. Patients
should not double their next dose or take more than the prescribed dose.
Special populations
Elderly patients
No dose adjustment is required for patients over 65 years (see sections 5.1 and 5.2).
Renal impairment
No dose adjustment of LIVTENCITY is required for patients with mild, moderate or severe renal
impairment. Administration of LIVTENCITY in patients with end stage renal disease (ESRD),
including patients on dialysis, has not been studied. No dose adjustments is expected to be required for
patients on dialysis due to the high plasma protein binding of maribavir (see section 5.2).
Hepatic impairment
No dose adjustment of LIVTENCITY is required for patients with mild (Child-Pugh Class A) or
moderate hepatic impairment (Child-Pugh Class B). Administration of LIVTENCITY in patients with
severe hepatic impairment (Child-Pugh Class C) has not been studied. It is not known whether
exposure to maribavir will significantly increase in patients with severe hepatic impairment.
Therefore, caution is advised when LIVTENCITY is administered to patients with severe hepatic
impairment (see section 5.2).
Paediatric population
The recommended dosing regimen in pediatric patients 12 years of age and older and weighing at least
35 kg is the same as that in adults. Use of LIVTENCITY in this age group is based on the following:
• Evidence from controlled studies of LIVTENCITY in adults
• Population pharmacokinetic (PK) modeling and simulation demonstrating that age and body weight
had no clinically meaningful effect on plasma exposures of LIVTENCITY
• LIVTENCITY exposure is expected to be similar between adults and children 12 years of age and
older and weighing at least 35 kg
• The course of the disease is similar between adults and pediatric patients to allow extrapolation of
data in adults to pediatric patients (see sections 5.1 and 5.2)
The safety and effectiveness of LIVTENCITY have not been established in children younger than 12
years of age.

Method of administration
Oral use.
LIVTENCITY is intended for oral use only and can be taken with or without food. The immediaterelease
tablets can be taken as whole, dispersed or crushed tablets by mouth, or as dispersed tablets
through a nasogastric or orogastric tube (French size 10 or larger). The suspension may be prepared
ahead of time and stored at a temperature of 68°F to 77°F (20°C to 25°C) for up to 8 hours.
Administration of Dispersed Tablets or Crushed Tablets by Mouth
1. Place the appropriate number of tablets for the prescribed dose into a suitable container. If
desired, the tablets may be crushed. Add the appropriate volume of drinking water (other
liquids have not been tested) to make a suspension (see Table 1 below).
Table 1: Number of Tablets and Volume of Drinking Water Needed to Make a Suspension for
Administration of Dispersed or Crushed Tablets by Mouth

2. Swirl the container gently to keep the particles from settling, and administer the suspension
before it settles. The mixture will have a bitter taste.
3. Rinse the container with 15 mL of drinking water and administer the rinse water.
4. Repeat Step 3. Visually confirm that no particles are left in the container. If particles remain,
repeat Step 3.

Administration of Dispersed Tablets through a Nasogastric (NG) or Orogastric (OG) Tube
1. Remove the cap (if applicable) and plunger out of a 50 or 60 mL catheter-tip compatible syringe
or equivalent. Add two tablets into the syringe body and place the plunger back in the syringe.
Only two tablets can be administered via NG or OG tube at a time.
2. Draw 30 mL of drinking water (other liquids have not been tested) into the syringe and hold the
syringe with the tip pointing upward. Pull the plunger further to a higher volume position to
have some air space in the syringe. Place the cap back on the syringe (if applicable). Shake the
syringe well (careful not to spill the contents) for about 30 to 45 seconds or until the tablets
are completely dispersed.
3. Once the tablets are completely dispersed in the syringe, remove the cap from the syringe again
(if applicable) and attach the syringe to the NG or OG tube and administer the dispersion
before it settles.
4. Draw 15 mL of water using the same syringe and flush through the same NG or OG tube.
5. Repeat Step 4 and make sure no particles are left in the syringe by visual inspection. If particles
remain, repeat Step 4.
6. For doses of 800 mg (four 200 mg tablets) and 1,200 mg (six 200 mg tablets), repeat Steps 1-5
until prescribed dose is reached. The same syringe, NG or OG tube can be used.

Virologic failure during treatment and relapse post-treatment
Virologic failure can occur during and after treatment with LIVTENCITY. Virologic relapse during
the post-treatment period usually occurred within 4-8 weeks after treatment discontinuation. Some
maribavir pUL97 resistance-associated substitutions confer cross-resistance to ganciclovir and
valganciclovir. CMV DNA levels should be monitored and resistance mutations should be
investigated in patients who do not respond to treatment. Treatment should be discontinued if
maribavir resistance mutations are detected.
CMV disease with CNS involvement
LIVTENCITY was not studied in patients with CMV CNS infection. Based on nonclinical data, CNS
penetration of maribavir is expected to be low compared to plasma levels (section 5.2 and 5.3).
Therefore, LIVTENCITY is not expected to be effective in treating CMV CNS infections (e.g.
meningo-encephalitis).
Use with immunosuppressants
LIVTENCITY has the potential to increase the concentrations of immunosuppressants that are
cytochrome P450 (CYP)3A/P-gp substrates with narrow therapeutic margins (including tacrolimus,
cyclosporine, sirolimus and everolimus). The plasma levels of these immunosuppressants must be
frequently monitored throughout treatment with LIVTENCITY, especially following initiation and
after discontinuation of LIVTENCITY, and doses should be adjusted, as needed (see sections 4.5, 4.8
and 5.2).

Risk of adverse reactions or reduced therapeutic effect due to medicinal product interactions
The concomitant use of LIVTENCITY and certain medicinal products may result in known or
potentially significant medicinal product interactions, some of which may lead to:
 possible clinically significant adverse reactions from greater exposure of concomitant
medicinal products.
 reduced therapeutic effect of LIVTENCITY.
See Table 2 for steps to prevent or manage these known or potentially significant medicinal product
interactions, including dosing recommendations (see sections 4.3 and 4.5).
Sodium content
This medicinal product contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially
‘sodium-free’.

Effect of other medicinal products on maribavir
Maribavir is primarily metabolised by CYP3A, and medicinal products that induce or inhibit CYP3A
are expected to affect the clearance of maribavir (see section 5.2).
Co-administration of maribavir and medicinal products that are inhibitors of CYP3A may result in
increased plasma concentrations of maribavir (see section 5.2). However, no dose adjustment is
needed when maribavir is co-administered with CYP3A inhibitors.
Concomitant administration of strong or moderate CYP3A inducers, (such as rifampicin, rifabutin,
carbamazepine, phenobarbital, phenytoin, efavirenz and St John’s wort), is expected to significantly

decrease maribavir plasma concentrations, which may result in decrease in efficacy. Therefore,
alternative medicinal products with no CYP3A induction potential should be considered. Coadministration
of maribavir with strong cytochrome P450 3A (CYP3A) inducers rifampicin, rifabutin
or St. John’s wort is not recommended.
If co-administration of maribavir with other strong or moderate CYP3A inducers (e.g., carbamazepine,
efavirenz, phenobarbital and phenytoin) cannot be avoided, the maribavir dose should be increased to
1 200 mg twice daily (see sections 4.2 and 5.2).
Effect of maribavir on other medicinal products

Co-administration of maribavir with valganciclovir and ganciclovir is contraindicated (see section
4.3). LIVTENCITY may antagonise the antiviral effect of ganciclovir and valganciclovir by inhibiting
human CMV UL97 serine/threonine kinase, which is required for activation/phosphorylation of
ganciclovir and valganciclovir (see sections 4.3 and 5.1).
At therapeutic concentrations, clinically relevant interactions are not expected when maribavir is coadministered
with substrates of CYP1A2, 2A6, 2B6, 2C8, 2C9, 2C19, 2E1, 2D6, and 3A4; UGT1A1,
1A4, 1A6, 1A9, 2B7; bile salt export pump (BSEP); multidrug and toxin extrusion protein
(MATE)/2K; organic anion transporters (OAT)1; organic cation transporters (OCT)1 and OCT2;
organic anion transporting polypeptide (OATP)1B1 and OATP1B3 based on in vitro and clinical
interaction results (Table 2 and section 5.2).
Maribavir acted as an inducer of CYP1A2 enzyme in vitro. There are no clinical data available to
exclude an interaction risk via CYP1A2 induction in vivo. Therefore, the concomitant administration
of maribavir and medicinal products that are sensitive substrates of CYP1A2 with a narrow therapeutic
window (e.g., tizanidine and theophylline) should be avoided due to the risk for lack of efficacy of
CYP1A2 substrates.
Co-administration of maribavir increased plasma concentrations of tacrolimus (see Table 2). When the
immunosuppressants tacrolimus, cyclosporine, everolimus or sirolimus are co-administered with
maribavir, immunosuppressant levels should be frequently monitored throughout treatment with
maribavir, especially following initiation and after discontinuation of maribavir and dose adjusted,
when needed (see sections 4.4 and Table 2).
Maribavir inhibited P-gp transporter in vitro at clinically relevant concentrations. In a clinical study,
co-administration of maribavir increased plasma concentrations of digoxin (see Table 2 Therefore,
caution should be exercised when maribavir and sensitive P-gp substrates (e.g., digoxin, dabigatran)
are co-administered. Serum digoxin concentrations should be monitored, and dose of digoxin may
need to be reduced, as needed (see Table 2).

Maribavir inhibited BCRP transporter in vitro at clinically relevant concentrations. Therefore,
co-administration of maribavir with sensitive BCRP substrates such as rosuvastatin, is expected to
increase their exposure and lead to undesirable effects.
In vitro, maribavir inhibits OAT3, therefore, plasma concentrations of medicinal products transported
by OAT3 may be increased (e.g.: ciprofloxacin, imipenem, and cilastatin).
In vitro, maribavir inhibits MATE1. There are no clinical data available whether the co-administration
of maribavir with sensitive MATE1 substrates (e.g., metformin) could potentially lead to clinically
relevant interactions.
General information
If dose adjustments of concomitant medicinal products are made due to treatment with maribavir,
doses should be readjusted after treatment with maribavir is completed. Table 2 provides a listing of
established or potentially clinically significant medicinal product interactions. The medicinal product

interactions described are based on studies conducted with maribavir or are predicted medicinal
product interactions that may occur with maribavir (see sections 4.4 and 5.2).
Table 2: Interactions and dose recommendations with other medicinal products.

^{↑ = increase, ↓ = decrease, ↔ = no change
CI = Confidence Interval; SD = Single Dose; QD = Once Daily; BID = Twice Daily
*AUC0-∞ for single dose, AUC0-12 for twice daily dose daily.
Note: the table is not extensive but provides examples of clinically relevant interactions.
a Refer to the respective prescribing information.}

Paediatric population
Interaction studies have only been performed in adults.

Pregnancy
There are no data of maribavir use in pregnant women. Studies in animals have shown reproductive
toxicity (see section 5.3). LIVTENCITY is not recommended during pregnancy and in women of
childbearing potential not using contraception.
Maribavir is not expected to affect the plasma concentrations of systemically acting oral contraceptive
steroids (see Section 4.5).
Breast-feeding
It is unknown whether maribavir or its metabolites are excreted in human milk. A risk to the suckling
child cannot be excluded. Breast-feeding should be discontinued during treatment with LIVTENCITY.
Fertility
Fertility studies were not conducted in humans with LIVTENCITY. No effects on fertility or
reproductive performance were noted in rats in a combined fertility and embryofoetal development
study, however, a decrease in sperm straight line velocity was observed at doses ≥ 100 mg/kg/day
(which is estimated to be < 1 times the human exposure at the recommended human dose [RHD]).
There were no effects on reproductive organs in either males or females in nonclinical studies in rats
and monkeys (see section 5.3).

LIVTENCITY has no influence on the ability to drive and use machines.

Summary of the safety profile

Adverse events were collected during the treatment phase and follow‑up phase through Study Week 20 in the Phase 3 study (see section 5.1). The mean exposures (SD) for LIVTENCITY was 48.6 (13.82) days with a maximum of 60 days. The most commonly reported adverse reactions occurring in at least 10% of subjects in the LIVTENCITY group were: taste disturbance (46%), nausea (21%), diarrhoea (19%), vomiting (14%) and fatigue (12%). The most commonly reported serious adverse reactions were diarrhoea (2%) and nausea, weight decreased, fatigue, immunosuppressant drug concentration level increased, and vomiting (all occurring at > 1%).

Tabulated list of adverse reactions

The adverse reactions are listed below by body system organ class and frequency. Frequencies are defined as follows: very common (≥ 1/10), common (≥ 1/100 to < 1/10), uncommon (≥ 1/1 000 to < 1/100), rare (≥ 1/10 000 to < 1/1 000) or very rare (< 1/10 000).

Table 3: Adverse reactions identified with LIVTENCITY

Description of selected adverse reactions

Taste disturbance

Taste disturbance (comprised of the reported preferred terms ageusia, dysgeusia, hypogeusia and taste disorder) occurred in 46% of patients treated with LIVTENCITY. These events rarely led to discontinuation of LIVTENCITY (0.9%) and, for most patients, resolved while patients remained on therapy (37%) or within a median of 7 days (Kaplan-Meier estimate, 95% CI: 4-8 days) after treatment discontinuation.

Increases in plasma levels of immunosuppressants

Immunosuppressant drug level increase (comprised of the preferred terms immunosuppressant drug level increased and drug level increased) occurred in 9% of patients treated with LIVTENCITY. LIVTENCITY has the potential to increase the drug concentrations of immunosuppressants that are CYP3A and/or P‑gp substrates with narrow therapeutic ranges (including tacrolimus, cyclosporine, sirolimus and everolimus). (See sections 4.4, 4.5 and 5.2).

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via:

To reports any side effect(s):

·   Saudi Arabia:

·   Other GCC States:

In Study 303, an accidental overdose of a single extra dose occurred in 1 LIVTENCITY‑treated subject on Day 13 (1 200 mg total daily dose). No adverse reactions were reported.

In Study 202, 40 subjects were exposed to doses of 800 mg twice daily and 40 subjects were exposed to 1 200 mg twice daily for a mean of approximately 90 days. In Study 203, 40 subjects were exposed to doses of 800 mg twice daily and 39 subjects were exposed to 1 200 mg twice daily for a maximum of 177 days. There were no appreciable differences in the safety profile in either study compared to the 400 mg twice daily group in Study 303 in which subjects received maribavir for a maximum of 60 days.

There is no known specific antidote for maribavir. In case of overdose, it is recommended that the patient be monitored for adverse reactions and appropriate symptomatic treatment instituted. Due to the high plasma protein binding of maribavir, dialysis is unlikely to reduce plasma concentrations of maribavir significantly.

Pharmacotherapeutic group: Antivirals for systemic use, direct acting antivirals, ATC code: J05AX10.

Mechanism of action

Maribavir is a competitive inhibitor of the UL97 protein kinase. UL97 inhibition occurs at the viral DNA replication phase, inhibiting UL97 serine/threonine kinase by competitively inhibiting the binding of ATP to the kinase ATP-binding site, without affecting the concatemer maturation process, abolishing phosphotransferase inhibiting CMV DNA replication and maturation, CMV DNA encapsidation, and CMV DNA nuclear egress.

Antiviral activity

Maribavir inhibited human CMV replication in virus yield reduction, DNA hybridization, and plaque reduction assays in human lung fibroblast cell line (MRC-5), human embryonic kidney (HEK), and human foreskin fibroblast (MRHF) cells. The EC₅₀ values ranged from 0.03 to 2.2 µM depending on the cell line and assay endpoint. The cell culture antiviral activity of maribavir has also been evaluated against CMV clinical isolates. The median EC₅₀ values were 0.1 μM (n=10, range 0.03-0.13 μM) and 0.28 μM (n=10, range 0.12-0.56 μM) using DNA hybridization and plaque reduction assays, respectively. No significant difference in EC₅₀ values across the four human CMV glycoprotein B genotypes (N = 2, 1, 4, and 1 for gB1, gB2, gB3, and gB4, respectively) was seen.

Combination antiviral activity

When maribavir was tested in in vitro combination with other antiviral compounds, strong antagonism was seen with ganciclovir.

No antagonism was seen in combination with cidofovir, foscarnet and letermovir.

Viral resistance

In cell culture

Maribavir does not affect the UL54encoded DNA polymerase that, when presenting certain mutations, confers resistance to ganciclovir/valganciclovir, foscarnet and/or cidofovir. Mutations conferring resistance to maribavir have been identified on gene UL97: L337M, F342Y, V353A, V356G, L397R, T409M, H411L/N/Y, D456N, V466G C480F, P521L, and Y617del. These mutations confer resistance that ranges from 3.5‑fold to > 200-fold increase in EC₅₀ values. UL27 gene variants (R233S, W362R, W153R, L193F, A269T, V353E, L426F, E22stop, W362stop, 218delC, and 301311del) conferred only mild maribavir resistance (< 5fold increase in EC₅₀), while L335P conferred high maribavir resistance.

In clinical studies

In Phase 2 Study 202 and Study 203 evaluating maribavir in 279 HSCT or SOT recipients, post‑treatment pUL97 genotyping data from 23 of 29 patients who initially achieved viremia clearance and later experienced recurrent CMV infection while on maribavir showed 17 patients with mutations T409M or H411Y and 6 patients with mutation C480F. Among 25 patients who did not respond to > 14 days of maribavir therapy, 9 had mutations T409M or H411Y, and 5 patients had mutation C480F. Additional pUL27 genotyping was performed on 39 patients in Study 202 and 43 patients in Study 203. The only resistance‑associated amino acid substitution in pUL27 that was not detected at baseline was G344D. Phenotypic analysis of pUL27 and pUL97 recombinants showed that pUL97 mutations T409M, H411Y, and C480F conferred 78‑fold, 15‑fold, and 224‑fold increases, respectively, in maribavir EC₅₀ compared with the wild‑type strain, whereas the pUL27 mutation G344D showed no difference in maribavir EC₅₀ as compared to the wild-type strain.

In Phase 3 Study 303 evaluating maribavir in patients with phenotypic resistance to valganciclovir/ganciclovir, DNA sequence analysis of the entire coding regions of pUL97 and pUL27 was performed on 134 paired sequences from maribavir-treated patients. The treatment-emergent pUL97 substitutions F342Y (4.5-fold), T409M (78-fold), H411L/N/Y (69-, 9-, and 12-fold, respectively), and/or C480F (224-fold) were detected in 60 subjects and were associated with non-response (47 subjects were on-treatment failures and 13 subjects were relapsers). One subject with the pUL27 L193F substitution (2.6-fold reduced susceptibility to maribavir) at baseline did not meet the primary endpoint. In addition, the following multiple mutations were associated with non-response; F342Y+T409M+H411N (78-fold), C480F+H411L+H411Y (224-fold), F342Y+H411Y (56-fold), T409M+C480F (224-fold) and H411Y+C480F (224-fold).

Cross resistance

Cross-resistance has been observed between maribavir and ganciclovir/valganciclovir (vGCV/GCV) in cell culture and in clinical studies. In the phase 3 Study 303, a total of 44 patients in the maribavir arm had a treatment emergent resistance associated substitutions (RAS) to Investigator assigned treatment (IAT). Of these 24 had treatment-emergent C480F or the F342Y RAS, both are cross-resistant to both ganciclovir/valganciclovir and maribavir. Of these 24 patients, 1 (0.04%) achieved the primary endpoint. Overall, only eight of these 44 patients achieved the primary endpoint.

pUL97 vGCV/GCV resistance-associated substitutions F342S/Y, K355del, V356G, D456N, V466G, C480R, P521L, and Y617del reduce susceptibility to maribavir > 4.5-fold. Other vGCV/GCV resistance pathways have not been evaluated for cross-resistance to maribavir. pUL54 DNA polymerase substitutions conferring resistance to vGCV/GCV, cidofovir, or foscarnet remained susceptible to maribavir.

Substitutions pUL97 F342Y and C480F are maribavir treatment-emergent resistance-associated substitutions that confer > 1.5-fold reduced susceptibility to vGCV/GCV, a fold reduction that is associated with phenotypic resistance to vGCV/GCV. The clinical significance of this cross-resistance to vGCV/GCV for these substitutions has not been determined. Maribavir resistant virus remained susceptible to cidofovir and foscarnet. Additionally, there are no reports of any pUL27 maribavir resistance-associated substitutions being evaluated for vGCV/GCV, cidofovir, or foscarnet cross-resistance. Given the lack of resistance-associated substitutions for these drugs mapping to pUL27, cross-resistance is not expected for pUL27 maribavir substitutions.

Clinical efficacy

A Phase 3, multi‑centre, randomised, open‑label, active‑controlled superiority study (Study SHP620‑303) assessed the efficacy and safety of LIVTENCITY treatment compared to Investigator assigned treatment (IAT) in 352 HSCT and SOT recipients with CMV infections that were refractory to treatment with ganciclovir, valganciclovir, foscarnet, or cidofovir, including CMV infections with or without confirmed resistance to 1 or more anti‑CMV agents. Refractory CMV infection was defined as documented failure to achieve > 1 log10 decrease in CMV DNA level in whole blood or plasma after a 14-day or longer treatment period with intravenous ganciclovir/oral valganciclovir, intravenous foscarnet, or intravenous cidofovir. This definition was applied to the current CMV infection and the most recently administered anti-CMV agent.

Patients were stratified by transplant type (HSCT or SOT) and screening CMV DNA levels and then randomised in a 2:1 ratio to receive LIVTENCITY 400 mg twice daily or IAT (ganciclovir, valganciclovir, foscarnet, or cidofovir) for an 8-week treatment period and a 12 week follow‑up phase.

The mean age of trial subjects was 53 years and most subjects were male (61%), white (76%) and not Hispanic or Latino (83%), with similar distributions across the two treatment arms. Baseline disease characteristics are summarised in Table 4 below.

Table 4: Summary of the baseline disease characteristics of the study population in Study 303.

^{CMV=cytomegalovirus, DNA=deoxyribonucleic acid, HSCT=haematopoietic stem cell transplant, IAT=investigator assigned anti-CMV treatment, max=maximum, min=minimum, N=number of patients, SD=standard deviation, SOT=solid organ transplant.
a Baseline was defined as the last value on or before the first dose date of study-assigned treatment, or date of randomisation for patients who did not receive study-assigned treatment.
b Age was calculated as the difference between date of birth and date of informed consent, truncated to years.}

^{c Percentages are based on the number of subjects in the Randomized set within each column. Most recent anti-CMV agent, used to confirm refractory eligibility criteria.}

^{d The most recent transplant.}

^{e Percentages are based on the number of patients within the category.}

^{f Viral load was defined for analysis by the baseline central specialty laboratory plasma CMV DNA qPCR results as high (≥91,000 IU/mL), intermediate (≥ 9,100 and < 91,000 IU/mL), and low (< 9,100 IU/mL).}

^{g Confirmed by Endpoint Adjudication Committee (EAC).}

^{h Patients could have CMV syndrome and tissue invasive disease.}

The primary efficacy endpoint was confirmed CMV viraemia clearance (plasma CMV DNA concentration below the lower limit of quantification (< LLOQ; i.e., < 137 IU/mL) at Week 8 regardless of whether either study-assigned treatment was discontinued before the end of the stipulated 8 weeks of therapy. The key secondary endpoint was CMV viraemia clearance and CMV infection symptom control at Week 8 with maintenance of this treatment effect through Study Week 16. CMV infection symptom control was defined as resolution or improvement of tissue‑invasive disease or CMV syndrome for symptomatic patients at baseline, or no new symptoms for patients who were asymptomatic at baseline.

For the primary endpoint, LIVTENCITY was superior to IAT (56% vs. 24%, respectively, p < 0.001). For the key secondary endpoint, 19% vs. 10% achieved both CMV viraemia clearance and CMV infection symptom control in the LIVTENCITY and IAT group, respectively (p=0.013) (See Table 5).

Table 5: Primary and key secondary efficacy endpoint analysis (randomised set) in Study 303

^{CI=confidence interval; CMV=cytomegalovirus; HSCT=haematopoietic stem cell transplant; IAT=investigator‑assigned anti‑CMV treatment; N=number of patients; SOT=solid organ transplant.}

^{a Cochran-Mantel‑Haenszel weighted average approach was used for the adjusted difference in proportion (maribavir‑IAT), the corresponding 95% CI, and the p‑value after adjusting for the transplant type and baseline plasma CMV DNA concentration.}

^{b CMV infection symptom control was defined as resolution or improvement of tissue‑invasive disease or CMV syndrome for symptomatic patients at baseline, or no new symptoms for patients who were asymptomatic at baseline.}

The treatment effect was consistent across transplant type, age group, and the presence of CMV syndrome/disease at baseline. However, LIVTENCITY was less effective against subjects with increased CMV DNA levels (≥ 50 000 IU/mL) and patients with absence of genotypic resistance (see table 6).

Table 6: Percentage of Responders by subgroup in Study 303

CMV=cytomegalovirus, DNA=deoxyribonucleic acid, HSCT=hematopoietic stem cell transplant, SOT=solid organ transplant

Recurrence

The secondary endpoint of recurrence of CMV viraemia was reported in 57% of the maribavir treated patients and in 34% of the IAT treated patients. Of these, 18% in the maribavir group had recurrence of CMV viraemia while on-treatment compared to 12% the IAT group. Recurrence of CMV viraemia during follow up was seen in 39% of patients in the maribavir group and in 22% of the patients in the IAT group.

Overall mortality: All-cause mortality was assessed for the entire study period. A similar percentage of subjects in each treatment group died during the trial (LIVTENCITY 11% [27/235]; IAT 11% [13/117]).

Maribavir pharmacological activity is due to the parent medicinal product. The pharmacokinetics of maribavir have been characterised following oral administration in healthy subjects and transplant patients. Maribavir exposure increased in an approximately dose proportionally manner. In healthy subjects, the geometric mean steady-state AUC0-t, Cmax and Ctrough values were 101 μg*h/mL, 16.4 μg/mL and 2.89 μg/mL, respectively, following 400 mg twice daily oral maribavir doses.
In transplant recipients, maribavir steady state exposure following oral administration of 400 mg twice daily doses are provided below, based on a population pharmacokinetics analysis. Steady-state was reached in 2 days, with an accumulation ratio of 1.47 for AUC and 1.37 for Cmax. The intrasubject variability (< 22%) and intersubject variability (< 37%) in maribavir PK parameters are low to moderate.

Table 7: Maribavir pharmacokinetic properties in transplant recipients based on a population pharmacokinetics analysis

Absorption

Maribavir was rapidly absorbed with peak plasma concentrations occurring 1.0 to 3.0 hours post dose. Exposure to maribavir is unaffected by crushing the tablet, administration of crushed tablet through nasogastric (NG)/orogastric tubes or co‑administration with proton pump inhibitors (PPIs), histamine H₂ receptor antagonists (H₂ blockers) or antacids.

Effect of food

In healthy subjects, oral administration of a single 400 mg dose of maribavir with a high fat meal resulted in no change in the overall exposure (AUC) and a 28% decrease in C_max of maribavir, which was not considered clinically relevant.

Distribution

Based on population pharmacokinetic analyses, the apparent steady‑state volume of distribution is estimated to be 27.3 L.

In vitro binding of maribavir to human plasma proteins was 98.0% over the concentration range of 0.05‑200 μg/mL. Ex vivo protein binding of maribavir (98.5%‑99.0%) was consistent with in vitro data, with no apparent difference observed among healthy subjects, subjects with hepatic (moderate) or renal (mild, moderate or severe) impairment, human immunodeficiency virus (HIV) patients, or transplant patients.

Maribavir may cross the blood‑brain barrier in humans but CNS penetration is expected to be low compared to plasma levels (see section 4.4 and 5.3).

In vitro data indicate that maribavir is a substrate of P-glycoprotein (P-gp), breast cancer resistance protein (BCRP) and organic cation transporter 1 (OCT1) transporters. Changes in maribavir plasma concentrations due to inhibition of P-gp/BCRP/OCT1 were not clinically relevant.

Biotransformation

Maribavir is primarily eliminated by hepatic metabolism via CYP3A4 (primary metabolic pathway fraction metabolised estimated to be at least 35%), with secondary contribution from CYP1A2 (fraction metabolised estimated at no more than 25%). The major metabolite of maribavir is formed by N‑dealkylation of the isopropyl moiety and is considered pharmacologically inactive. The metabolic ratio for this major metabolite in plasma was 0.15‑0.20. Multiple UGT enzymes, namely UGT1A1, UGT1A3, UGT2B7, and possibly UGT1A9, are involved in the glucuronidation of maribavir in humans, however, the contribution of glucuronidation to the overall clearance of maribavir is low based on in vitro data.

Based on in vitro studies, metabolism of maribavir is not mediated by CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP3A5, 1A4, UGT1A6, UGT1A10, or UGT2B15.

Elimination

The elimination half‑life and oral clearance of maribavir are estimated at 4.3 hours and 2.9 L/h, respectively, in transplant patients. After single dose oral administration of [¹⁴C]‑maribavir, approximately 61% and 14% of the radioactivity were recovered in urine and faeces, respectively, primarily as the major and inactive metabolite. Urinary excretion of unchanged maribavir is minimal.

Special populations

Renal impairment

No clinically significant effect of mild, moderate or severe renal impairment (measured creatinine clearance ranging from 12 to 70 mL/min) was observed on maribavir total PK parameters following a single dose of 400 mg maribavir. The difference in maribavir PK parameters between subjects with mild/moderate or severe renal impairment and subjects with normal renal function was < 9%. As maribavir is highly bound to plasma proteins, it is unlikely that maribavir will be significantly removed by haemodialysis or peritoneal dialysis.

Hepatic impairment

No clinically significant effect of moderate hepatic impairment (Child‑Pugh Class B, score of 7‑9) was observed on total or unbound maribavir PK parameters following a single dose of 200 mg of maribavir. Compared to the healthy control subjects, AUC and C_max were 26% and 35% higher, respectively, in subjects with moderate hepatic impairment. It is not known whether the exposure to maribavir will increase in patients with severe hepatic impairment.

Age, gender, race, ethnicity, and weight

Age (18‑79 years), gender, race (Caucasian, Black, Asian, or others), ethnicity (Hispanic/Latino or non‑Hispanic/Latino) and body weight (36 to 141 kg) did not have clinically significant effect on the pharmacokinetics of maribavir based on population PK analysis.

Pediatric Patients
The pharmacokinetics of maribavir in patients less than 18 years of age have not been evaluated.
Using modeling and simulation, the recommended dosing regimen is expected to result in comparable steady-state plasma exposures of maribavir in patients 12 years of age and older and weighing at least 35 kg as observed in adults (see section 4.2).

Transplant types

Transplant types (HSCT vs. SOT) or between SOT types (liver, lung, kidney, or heart) or presence of gastrointestinal (GI) graft‑versus host disease (GvHD) do not have a clinically significant impact on PK of maribavir.

General
Regenerative anaemia and mucosal cell hyperplasia in the intestinal tract, observed with dehydration
was noted in rats and monkeys, together with clinical observations of soft to liquid stool, and
electrolyte changes (in monkeys only). A no observed adverse effect level (NOAEL) was not
established in monkeys and was < 100 mg/kg/day, which is approximately 0.25 the human exposure at
the recommended human dose (RHD). In rats the NOAEL was 25 mg/kg/day, at which exposures
were 0.05 and 0.1 times the human exposure at the RHD in males and females, respectively.
Maribavir did not demonstrate phototoxicity in vitro, therefore, the potential for phototoxicity in
humans is considered unlikely.
Maribavir was detected at low levels in the choroid plexus of rats and the brain and CSF of the
monkey (see section 4.4 and 5.2).
Carcinogenesis
No carcinogenic potential was identified in rats up to 100 mg/kg/day at which exposures in males and
females were 0.2 and 0.36 times, respectively the human exposure at the RHD. In male mice, an
equivocal elevation in the incidence of haemangioma, haemangiosarcoma, and combined
haemangioma/ haemangiosarcoma across multiple tissues at 150 mg/kg/day is of uncertain relevance
in terms of its translation to human risk given the lack of an effect in female mice or in rats after
104 weeks of administration, lack of neoplastic proliferative effects in male and female mice after
13 weeks administration, the negative genotoxicity package and the difference in duration of
administration in humans. There were no carcinogenic findings at the next lower dose of
75 mg/kg/day, which is approximately 0.35 and 0.25 in males and females, respectively, the human
exposure at the RHD.
Mutagenesis
Maribavir was not mutagenic in a bacterial mutation assay, nor clastogenic in the bone marrow
micronucleus assay. In mouse lymphoma assays, maribavir demonstrated mutagenic potential in the
absence of metabolic activation and the results were equivocal in the presence of metabolic activation.
Overall, the weight of evidence indicates that maribavir does not exhibit genotoxic potential.
Reproduction
Fertility
In the combined fertility and embryofoetal development study in rats, there were no effects of
maribavir on fertility. However, in male rats decreases in sperm straight line velocity, were observed
at doses ≥ 100 mg/kg/day (which is estimated to be less than the human exposure at the RHD), but
without any impact on male fertility.
Prenatal and postnatal development
In a combined fertility and embryofoetal development study in rats, maribavir was not teratogenic and
had no effect on embryofoetal growth or development at doses up to 400 mg/kg/day. A decrease in the
number of viable foetuses due to increase in early resorptions and post-implantation losses was
observed in females at all tested maribavir doses which were also maternally toxic. The lowest dose
corresponded to approximately half the human exposure at the RHD. In the pre and postnatal
developmental toxicity study conducted in rats, decreased pup survival due to poor maternal care and
reduced body weight gain associated with a delay in developmental milestones (pinna detachment, eye
opening and preputial separation) were observed at maribavir doses ≥ 150 mg/kg/day. Postnatal
development was not affected at 50 mg/kg/day. Fertility and mating performance of the F1 generation,
and their ability to maintain pregnancy and to deliver live offspring, was unaffected up to
400 mg/kg/day.
In rabbits, maribavir was not teratogenic at doses up to 100 mg/kg/day (approximately 0.45 times the
human exposure at the RHD).

Tablet core
Microcrystalline cellulose (E460(i))
Sodium starch glycolate
Magnesium stearate (E470b)
Film-coating
Polyvinyl alcohol (E1203)
Macrogol (polyethylene glycol) (E1521)
Titanium dioxide (E171)
Talc (E553b)
Brilliant blue FCF aluminum lake (EU) (E133)

Not applicable.

Do not store above 30 °C.

High-density polyethylene (HDPE) bottles with child resistant cap.
Pack-sizes of 28 or 56 film-coated tablets.
Not all pack sizes may be marketed.

Any unused medicinal product or waste material should be disposed of in accordance with local
requirements.